bezuclastinib

Small molecule

Filedunder review

Evidence outlook · regulatory review

Gastrointestinal Stromal Tumor: application under FDA review, decision date 2026-11-30

FDA grants Priority Review for bezuclastinib NDA in GIST (2026-05-28). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Latest reported trial: NCT05208047 · Phase 3 · met primary endpoint · grade pending

Also in development:Systemic Mastocytosis · Phase 2 · under FDA review

Source for the program status

Company guidance: regulatory decision expected later this year (Cogent Biosciences, Inc., 10 Aug 2026). “On track for potential approval of bezuclastinib for GIST patients (PDUFA November 30) and NonAdvSM patients (PDUFA December 30) later this year; AdvSM New Drug Application submitted to FDA on June 30” Source ↗

Company guidance: regulatory filing expected Q4 2026 (Cogent Biosciences, Inc., 30 Jun 2026). “APEX NDA is third submission for bezuclastinib in six months; PEAK and SUMMIT reviews ongoing and on track for anticipated Q4 2026 approval” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Gastrointestinal Stromal Tumor
Phase 2 (3)
Gastrointestinal Stromal Tumor
NCT06208748 · Sarcoma Alliance for Research through Collaboration
2024-08-01 – 2027-06 · Gastrointestinal Stromal Tumors, GIST
What this study did
Systemic Mastocytosis
Phase 1/2 (1)
Gastrointestinal Stromal Tumor
NCT02401815 · Cogent Biosciences, Inc.
2015-03-06 – 2020-05-11 · Gastrointestinal Stromal Tumors
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Gastrointestinal Stromal Tumor: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Bezuclastinib: this drugPhase 3Small moleculeKITnot yet gradedNo reviewed efficacy summary in this indication
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)not yet gradedNo reviewed efficacy summary in this indication
Barzolvolimab
Phase 3(overall)
Monoclonal antibodyKIT
Partial signal(overall)
No reviewed efficacy summary in this indication
VelzatinibPhase 3Small moleculeKITnot yet gradedNo reviewed efficacy summary in this indication
Briquilimab
Phase 1/2(overall)
Monoclonal antibodyKIT
Partial signal(overall)
No reviewed efficacy summary in this indication
SAR449028
—(overall)
UndisclosedKIT
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(9)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

30 November 2026FDA action datePDUFA date for bezuclastinib in GIST
US, FDA · Cogent Biosciences, Inc. · Source ↗
30 December 2026FDA action datePDUFA date for bezuclastinib in nonadvanced systemic mastocytosis
US, FDA · Cogent Biosciences, Inc. · Source ↗
29 June 2027FDA action datePDUFA date for bezuclastinib in advanced systemic mastocytosis
US, FDA · Cogent Biosciences, Inc. · Source ↗

Recent

15 September 2026Filing acceptedFDA accepts bezuclastinib NDA in advanced systemic mastocytosis
US, FDA · Cogent Biosciences, Inc. · Source ↗
30 June 2026Filing submittedNDA submitted for bezuclastinib in AdvSM
US, FDA · Source ↗
28 May 2026Filing acceptedFDA accepts bezuclastinib NDA in GIST (with sunitinib) and grants Priority Review
US, FDA · Cogent Biosciences, Inc. · Source ↗
28 May 2026Priority reviewFDA grants Priority Review for bezuclastinib NDA in GIST
US, FDA · Source ↗
16 March 2026Filing acceptedFDA accepts bezuclastinib NDA in nonadvanced systemic mastocytosis
US, FDA · Cogent Biosciences, Inc. · Source ↗
10 November 2025Topline resultPEAK Phase 3 (NCT05208047) met its primary endpoint of PFS
Cogent Biosciences · Source ↗